- UX
- December 2022
- Sandoz × Mirumee
Sandoz Rheumatism & Sandoz Learn
Two apps for doctors from the Sandoz ecosystem: choosing a rheumatism therapy and short videos attached to a prescription
With the Mirumee team I designed the UX of three Sandoz medical apps. Here are two of them: Rheumatism, where after three questions the doctor sees the drugs and the clinical guidelines, and Learn, where the doctor records a video for a patient who cannot read and prescribes it like a medicine — as a code on the prescription.
Illustration: a phone with the Sandoz Rheumatism survey, its answers ticking in one by one, and the Sandoz Learn library window printing out a code for the patient.
01 Brief
The right information, in a form people can take in
The project was to design the UX (wireframes) for three Sandoz medical apps. The first two are for the doctor — and each delivers information in a different form.
Rheumatism takes the doctor from three answers to the drugs and the clinical guidelines. Learn turns the doctor’s advice into a video the patient can play in any phone’s browser — even if they cannot read.
The doctor · a web app
Sandoz Rheumatism
A survey: symptom severity, treatment stage and therapy type. Then the drugs grouped by mechanism of action or by guideline, and a therapy card for each.
To the surveyThe doctor and the patient · the Global South
Sandoz Learn
The doctor records short videos or picks them from the Sandoz library and prescribes them to the patient with one code. The patient plays them in any phone’s browser.
To recordingThe patient · SMS and an app
Sandoz Health
The third and the most advanced: a health programme “prescribed” with a code, over SMS or in an app. It has its own presentation with a working prototype.
The Sandoz Health presentation
About the project
- Client
- Sandoz × Mirumee
- When
- December 2022
- Location
- Basel, Switzerland
- Team
- Head of Design: Iwo Rzepiela · UX: Jakub Nowak
- Scope
- UX (wireframes) of three apps
Sandoz is a global maker of generic and biosimilar medicines, founded in Switzerland in 1886.
It works in more than 160 countries. Learn was made for the Global South and for patients who cannot read.
Part A · Sandoz Rheumatism
02 Survey
Three questions, one path
The survey helps the doctor choose a rheumatism therapy. It has three parts — Severity, Treatment and Therapy — and from the answers the app shows the drugs that follow the clinical guidelines.
A disclaimer first
The app makes no diagnosis and does not replace the doctor’s judgment — the way in is the button “Agree. I am a doctor.”
Severity
The doctor rates the patient’s symptoms: from mild to severe.
Treatment
The treatment stage: initial treatment, after initial treatment failure or after a TNF inhibitor failure.
Therapy
The therapy type: monotherapy or combined therapy.
The answers start as in the recording. Tap a step to change its answer, or clear the map and walk through the survey again — an answer closes its step and opens the next one at once.
RheumatismDisclaimer
About Sandoz Rheumatism App
Sandoz Rheumatism does not make a medical diagnosis and should not replace the judgment of a qualified medical professional. It provides information to help you make decisions based on readily available symptom information. If you have any questions or concerns about the results obtained from this app, consult with qualified medical personnel.
Wireframe content — this is not a medical tool
18 paths
3 × 3 × 2 answers. Every tick on the phone lights a path on the map — and the other way round: pick an answer here and the phone ticks it for you.
Matching paths: 1 of 18
Severity
Treatment
Therapy
03 Results
The same drugs, two ways to look
Step 4 shows the results: drugs split into groups with a similar mechanism of action, or ordered by clinical guideline. Unfolding a group lists the substances, and each one leads to its therapy card.
Molecule
cDMARDs, Biological DMARDs, Targeted synthetic DMARDs — the drugs by mechanism of action.
Guideline
NICE – TA715 and NICE – TA375 — the same substances by the guidelines that cover them.
- The recordings follow one path: moderate · after initial treatment failure · combined therapy.
- In the recording four biologics sit under cDMARDs — a wireframe placeholder. The replica files them under Biological DMARDs, as the therapy card labels them, and methotrexate under cDMARDs.
RheumatismWireframe content — this is not a medical tool
04 Therapy
A therapy card that remembers the answers
Clicking a substance opens its therapy description: warnings, the guidelines’ provisos and how the drug works. The survey’s answers stay at the top as switches, and for a combined therapy the card suggests the second drug.
The answers as switches
Severity and the treatment stage change without going back to the survey — a bottom sheet holds the same options.
The warning
When to withdraw the drug — from the guidelines, with a warning sign.
The guidelines’ proviso
What happens to patients who started treatment before the guidance came out.
About the drug
How it works and what it is for, folded to the first paragraph.
Combined therapy
“Recommended with” — the second drug, here methotrexate, with a short description.
Therapy details
Abatacept
Biological DMARDs
After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.
People whose treatment with adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab or abatacept is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.
Abatacept, trade name Orencia, is a type of drug called a biological therapy. It targets the cause of your inflammation and reduces the activity of your immune system. It’s an effective treatment for many people living with arthritis.
Recommended with
Wireframe content — this is not a medical tool
- In the recording, switching severity to severe ends in “No results — Choose a different guideline”. The replica shows it for every path but the recordings’ one.
- Only abatacept and methotrexate have descriptions. The other substances get their name, class and the screen’s skeleton.
- The phone’s texts are the wireframes’ placeholder content, taken from public material such as NICE guidance and Wikipedia.
Part B · Sandoz Learn
05 Recording
The doctor records, the patient needn’t read
Sandoz Learn is for doctors who want to communicate better with patients who cannot read or struggle to. The doctor records a short video: how to take the medicine, the disease’s symptoms, what to eat.
Rules before recording
No sensitive patient data, a careful background or a blurred one, and general enough to be useful at later visits.
Camera: video or audio
One record button, with background blur beside it and a Video | Audio switch.
The video in the corner, a drawing in the middle
The video can fill the screen or shrink to the bottom-right corner — then a drawing fills the main space and helps the patient follow.
A lesson in the library
After “Next” the video lands in the doctor’s library, where it gets a title, a description and drug and disease tags.
Shrink the video, turn on “Draw” and sketch on the blue background — like a doctor showing the dosage.
Lessons, codes and the patient’s data are samples
The recordings show a real person, so in the replica the doctor’s video is a drawing, and in the gallery’s material it is the wireframe’s placeholder.
06 Library
Your own videos and the Sandoz library in one grid
The doctor picks from their own recordings and Sandoz’s material on drugs and diseases — filtering by favourites, authorship, drug and disease, searching by keyword and selecting several lessons at once.
Tokens in the search
Type “Drug: A” or use the Drug + chip — the drug becomes a token, and a word beside it narrows the result, like “Warning” in the recording.
Who recorded it
Your authorship, Author: Sandoz and favourites. The icon under a thumbnail shows the author too.
The lesson card
The author, an editable description, the recording and subtitle languages, the drug, the disease and tags. “Prescribe to the patient” adds the lesson to the right panel.
The right panel
The chosen lessons wait on the right. The doctor can also type in a code the patient already has and add lessons to it.
Lessons, codes and the patient’s data are samples
Select lessons and generate a code — the replica takes you to § 07.
07 Code
A video on prescription, by code
The chosen lessons get one code. The doctor prints it and attaches it to the prescription, and the patient types the short address or scans the QR code with any phone that has a browser.
Lessons, codes and the patient’s data are samples
The replica’s QR code is a drawing — it leads to no address.
A short address
san.med and four digits — copied from paper, with no app and no sign-in.
A QR on the printout
The printout has the logo, the full address and the QR code — for the prescription.
A new code or new lessons
“New code” issues another code, “Edit content” goes back to choosing lessons.
08 Patient
Any phone, just a browser
After typing the address the patient is asked to turn on notifications, to get reminders about lessons matched to their disease and medicines. Then they watch or listen to what was prescribed.
New and watched
New lessons sit on top; watched ones move down.
Video or audio
Every lesson can be watched or just listened to.
Big buttons, little text
The list is a title and a big play button.
The list of lessons comes from the board. The notification prompt and the player are drawn from the case study’s description.
New
Completed
Get reminders about your lessons
Allow notifications and we will remind you when your doctor adds a lesson.
Lessons, codes and the patient’s data are samples
09 Boards
The wireframes from 2022
Five boards and four recordings from the case study. In the Learn material the wireframe’s placeholder stands in for the doctor’s video and its thumbnails.
The third app
Sandoz Health
Health monitoring over SMS, MMS and RCS or in an app — a separate presentation with a working prototype in Material 3 Expressive.
Sandoz, the Sandoz logo and the drug names are trademarks of their owners. The presentation shows a 2022 UX project; the replicas run on sample data, are not a medical device and do not replace medical advice.